Tinea Pedis Clinical Trial
Official title:
Clinical Study Protocol Number DBI-201. Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis
This is an open- label, single- dose, dose escalating evaluation of the safety and
tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
The purpose of the current protocol is to establish the safety and tolerability of a single
application of J. lividum to the feet of patients with proven T. pedis. In addition, the
effect of J liv on the T. pedis will also be evaluated.
Open- label, single- dose, dose escalating evaluation of the safety and tolerability of three
dose levels of DBI-001 in patients with Tinea pedis.
Study Objectives and Purpose The purpose of the study is to evaluate the safety and
tolerability of DBI-001 in patients with Tinea pedis. Secondly to evaluate presence or
persistence of J. lividum of DBI-001 following a single application of DBI-001. Thirdly to
see the effect on the abundance of T. rubrum. Lastly to see the effect of a single
application of DBI-001 on the signs and symptoms of interdigital T. pedis.
Tolerability will be evaluated through assessment of selected local signs and symptoms (pain
/ burning / stinging, pruritus, erythema, edema, and scabbing / crusting). Any local skin
reaction that requires use of a concomitant therapy or study discontinuation will be reported
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
| Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
| Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
| Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
| Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
| Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
| Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
| Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
| Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
| Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
| Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
| Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
| Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
| Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
| Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
| Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
| Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
| Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
| Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
| Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 |